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Simple Summary: Myxomatosis has affected the European domestic rabbit in Spain since the end
of 1953; and rabbit haemorrhagic disease (RHD) since mid-1988. In this study, we describe the
occurrence of myxomatosis; and RHD; on commercial rabbitries visited in Spain; between 1988 and
2018. Annual occurrence of myxomatosis decreased over 30 years. Cases of myxomatosis were
detected most frequently between August and March; more cases occurring in September and fewer in
June. Two important RHD epidemics occurred; the first in 1988–1989 due to classic RHD virus (RHDV),
and the second from 2011 to 2013 due to new calicivirus (RHDVb/RHDV2). Monthly occurrence of
RHD in 2011–2018 was higher from April to August. Despite seasonal variations of these diseases;
we recommend that young breeders and adults should be protected by vaccination all year round;
and on-farm hygiene measures implemented
Abstract: In this retrospective study, we describe the relative occurrence of clinical myxomatosis,
and rabbit haemorrhagic disease (RHD), on 1714 commercial farms visited in Spain, between 1988 and
2018. We determined the annual prevalence based on 817 visits to 394 farms affected by myxomatosis.
Myxomatosis was more prevalent from August to March, being lowest in June (3%) and highest in
September (8.9%). With regard to RHD, we assessed 253 visits to 156 affected farms. We analyzed
mean annual and monthly incidence. Two important RHD epidemics occurred; the first in 1988–1989
due to RHDV GI.1 (also known as RHDV), and the second from 2011 to 2013 due to RHDV GI.2
(RHDV2 or RHDVb). These epidemics occurred at times when effective vaccination had not been
carried out. Relative monthly incidence in 2011–2018 was higher from April to August (p < 0.001).
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The results we obtained from 1404 necropsies on 102 farms did not clearly relate serosanguinous nasal
discharge in rabbits with disease caused by GI.2 infection. We also assessed vaccination schedules
used on 200 doe farms visited from the end of 2014 to 2018; 95.5% vaccinated against myxomatosis
and 97.5% against RHD. Both diseases remain prevalent; however, effective vaccination has produced
a steady decline in myxomatosis and RHDV GI.1 and GI.2 on-farm detection. The maintenance of high
hygienic standards will be needed to continue and improve this control. However, further studies are
required to investigate the causes of sustained virus presence and vaccine breaks.
Keywords: animal welfare; disease prevention; myxomatosis prevalence; rabbit haemorrhagic
disease incidence
1. Introduction
The major viral diseases affecting the European domestic rabbit (Oryctolagus cuniculus) are
myxomatosis and rabbit haemorrhagic disease (RHD) and these have serious effects on the health and
welfare of rabbits [1]. The economic perspective is often considerable as an entire rabbitry might be
affected. The World Organization for Animal Health (OIE) includes myxomatosis and RHD on its list
of notifiable diseases [2]. The etiological agents of both diseases can be transmitted between domestic
and wild rabbits through the action of blood sucking/biting insects [3]. The effects of myxomatosis and
RHD on the health of wild rabbit populations also have consequences on related ecosystems [4].
Clinical myxomatosis frequently occurs in a subacute or chronic form, with severe productive
rhinitis and dyspnea [5,6]. Affected rabbits can have a rapid course to septicemia and death, or have
pulmonary lesions, blepharitis, aural, and urogenital swelling, and cutaneous myxomas or, in subacute
cases, bacterial superinfection [6,7]. In terms of pathogenicity and virulence, the immune suppressing
effect of some myxoma viruses [8] is of particular note.
RHD is characterized by disseminated necrotic hepatitis [9]; it evolves peracutely or acutely
with high mortality. Prior to death, clinical signs derive from severe disseminated intravascular
coagulopathy (DIC), with multi-organ failure [10], sometimes with asphyxia, seizures, and intense
suffering [11]. There is no treatment; vaccination is the only preventive measure, together with the
implementation of biosecurity measures [12].
Myxoma virus (MYXV) belongs to the Poxviridae family and the Leporipoxvirus genus. In Spain,
myxomatosis was first diagnosed in domestic rabbits towards the end of 1953 [13]. There were
outbreaks of classic or typical myxomatosis until 1978, with different degrees of cutaneous clinical
expression in the form of pseudotumors: myxomas [7], depending on the susceptibility of the rabbits
and viral strains involved [14]. From 1979 onwards, the presence of atypical myxomatosis was
described “with decreased cutaneous expression and continued respiratory problems” [7]. Since then,
outbreaks of both forms have occurred: classic and atypical or “amyxomatous”, mistakenly referred to
as “respiratory” [15]. In a previous study, based on 660 visited farms, we reported a seasonal variation
with an increase from October to December [16].
Although effective vaccines against myxomatosis have been available for some time the disease
persists. “Heterologous” vaccines based on the rabbit (Shope) fibroma virus have been used since 1955
and “homologous” vaccines (e.g., the SG 33 strain [17], León 162, and VMI 30 strains) since the 1980s
with different adjuvants, and administration routes: subcutaneous or intradermic [18–20].
RHD is caused by rabbit haemorrhagic disease virus (RHDV now termed RHDVG I.1 [21]).
In Spain, the first cases of RHD were identified in domestic rabbits in June 1988 [22] and soon after the
causative agent was identified by Parra and Prieto [23]. A specific vaccine against this RHDV strain
was used in Spain from January 1989, with protection shown to last over one year [24]. During the
following years, different RHD genogroups (e.g., GI.1a-d) were identified mainly in other European
countries [25,26], but had no serious effects on farms as the available vaccines proved effective (review
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in [27]). This could explain why the occurrence of RHD in domestic rabbits, was only serious at the
start of the 1988–1989 epidemics, coinciding with when the vaccine was not available [11]. Since 1999,
a combined vaccine with MYXV and GI.1 virus [28] has been available. Additionally, a bivalent
recombinant vaccine of homologous attenuated MYXV, which expresses GI.1 capsid protein (VP60)
has been on the market since 2012 [29]. In 2010, a novel RHDV was identified in France [30] and
subsequently in Spain: originally RHDV2 or RHDVb now termed RHDV GI.2, affecting rabbits under
35 days old [31] and vaccinated rabbits. The occurrence of disease due to GI.2 in Spain was serious
from 2011 until July 2013, when vaccines against it were first used [32].
Our aims were to (1) describe the procedures used for diagnosing clinical myxomatosis and RHD
on commercial farms between 1988 and 2018, (2) estimate myxomatosis prevalence through farm
visits over the 30-year period, (3) calculate the incidence of RHD, and (4), describe MYXV and RHDV
vaccination schedules on 200 rabbit doe farms visited from the end of 2014 to 2018.
2. Materials and Methods
Our 30-year study lasted from 11 September 1988, when we visited our first farm affected by
RHD, to 11 September 2018. We obtained information from a total of 13,467 visits to 1714 commercial
farms. The information gathered was used to generate a dataset with the number of adult breeding
rabbits per farm, and rabbit health management. Animal Care and Use Committee approval was not
obtained for this study because data were obtained from rabbits raised under commercial conditions,
fulfilling European, Spanish and regional recommendations and laws on animal welfare, food safety
and environmental protection.
2.1. Characteristics of the Farms Visited
This retrospective study included all the 1714 farms visited by the first author in Spain. They housed
females with or without males or weaned rabbits, only males, or only weaned rabbits. The target
populations included all types of rabbits because they were all at risk. Farms in Spain are inscribed in
the official database Registro General de explotaciones ganaderas (REGA). According to the Ministerio de
Agricultura, Pesca y Alimentación [33], the number of farms varied greatly throughout the 30-year period,
with a marked decrease in those housing >20 does; e.g., over 5000 farms in 1999, whereas in 2017 it had
decreased to fewer than 1000. In a preliminary paper [34], we provided a detailed explanation of the
farms registered in the REGA database and those visited between 2001 and 2017 (opus cit., Figure 1).
At the same time, the average size (number of does) of the farms increased. In addition, we have used
a subset of 200 farms housing does, that we have visited since the end of 2014 until the end of 2018,
to describe the vaccination programs, among other factors. In our case, a doe was a female that had
been serviced once or more.
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2.2. Veterinary Visits to the Rabbit Farms
In this study, the clinical information on myxomatosis and RHD was collected by the first author
who provided veterinary services to domestic rabbit producers and on-farm observation or examination
of the rabbits. All of the farms had been visited by other veterinarians. The visits were due to urgent
clinical calls, or to carry out routine check-ups. When classifying urgent visits, we only considered
the main cause; myxomatosis and RHD were always priority causes. Nevertheless, cases of zoonotic
diseases, e.g., salmonellosis [35], amongst others, were recorded for monitoring and surveillance
purposes. Producers were asked about different aspects, such as the number of existing females
or males, if any, per farm and the used lines, type of service: mount or artificial insemination (AI),
reproduction rhythm and number of batches per barn or farm, amongst others. In addition, we inquired
about myxomatosis and RHD vaccination schedules.
2.3. On-Farm Diagnostic Procedures
We observed signs of myxomatosis including prostration or dyspnea, and lesions such as
blepharitis and conjunctivitis, ear edema or myxomas. When we detected a suspected case, we checked
the anogenital region and palpated the skin for myxomas if they were not visible. These elements,
besides the epidemiological features often helped us to issue a presumptive diagnosis. So as to not
confound in the on-farm diagnosis, we collected samples for histopathologic study from farms with
only some doubtful sick rabbits, for diagnosis of myxoid tissue [36]. Images related to myxomatosis
may be seen on [37].
Animals 2019, 9, 780 5 of 16
Concerning RHDV GI.1, from 1988 we carried out a campaign of frequent visits, necropsies and
sample collection for laboratory analysis, where the O type human blood agglutination test [38] was
carried out. When the RHDV GI.2 epidemics occurred in 2011–2013, laboratory diagnosis consisted of
RT-PCR and sequencing similar to that described in [31,39] and when it became available with a rapid
field analytical test kit (CerTest Biotec, Zaragoza, Spain). We also necropsied adults, young rabbits and
weaned rabbits (>35 days old), and carried out histopathologic studies of rabbits under 25 days old.
Images related to RHD are available on [40].
2.4. Statistical Analysis
The database used contains 13,467 records (farm visits). The variables recorded were occurrence
of clinical myxomatosis and RHD (categorical variable) on each farm visit. The relative occurrence was
calculated dividing the number of myxomatosis or RHD cases by the total number visits. Following the
same procedure as in a preliminary study [16], we only used one visit per farm and calendar month,
at most, for these calculations; thus, the database for the analyses comprised a subset with 13,326 visits.
Concerning measures of disease occurrence, we followed the criterion of Thrusfield [41]. In the case of
clinical myxomatosis, we calculated relative annual and monthly relative prevalence; the reason for
this was that we visited farms where the disease could have been an enzootic pattern. In the case of
RHD, we analyzed the incidence because in the preliminary assessment of the time between the first
visit to each case of RHD and the first day with compatible losses on each farm, the results were as
follows: 50.5% of the 109 first-visits during 2011–2018 were made on the first 7 days of the apparent
start of each outbreak of RHD.
The analyses were carried out using the SAS statistical package, and the CATMOD, FREQ,
or MEAN procedures, depending on the analyses we used [42]. The statistical model (CATMOD
procedure) used was the following:
Yijk = µ + YEi +MOj +eijk (1)
where Yij were the dependent categorical variables, occurrence of myxomatosis or RHD on each
visit-farm, YEi was the year effect (30: from September 1988 until September 2018), MOj was the month
effect (12), and eijk was the residual effect. We have not analyzed covariates.
3. Results
3.1. Characteristics of the Visited Farms
Figure 1 shows the number of farms (1714 in total) visited per region in Spain over the
30-year period.
Throughout the study, the farms decreased in number but increased in size (Table 1). The total
number of farms visited represented 10-20% of Spanish farms, according to the year. Relative to data
in Table 1, with 3-year observation periods, there were in total 190 visits due to myxomatosis and
1618 visits (calendar month), from 11 September 1988 until 11 September 1991.
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Table 1. Visits for periods of three years due to myxomatosis (myxo.) and rabbit haemorrhagic disease
(RHD), and mean sizes (number of does) of farms visited from 1988 to 2018.
Annual Periods a N Visits(c)
N
Farms Mean Size
N Visits due to
myxo. (c)
N Farms with
myxo.
N Visits due to
RHD (c)
N Farms
with RHD
1988–1991 1633 (1618) 470 363 195 (190) 105 55 (45) 39
1991–1994 1256 (1252) 433 381 101 (97) 68 5 (5) 4
1994–1997 1292 (1291) 468 447 82 (81) 70 6 (6) 6
1997–2000 1107 (1104) 327 585 60 (57) 30 8 (8) 6
2000–2003 1231 (1231) 255 773 46 (46) 34 6 (6) 6
2003–2006 1065 (1058) 313 859 65 (58) 45 6 (6) 6
2006–2009 1269 (1268) 316 947 50 (49) 36 6 (6) 6
2009–2012 1818 (1806) 307 982 92 (88) 57 76 (58) 41
2012–2015 1465 (1401) 242 926 104 (92) 43 137 (85) 55
2015–2018 1331 (1312) 196 985 67 (59) 33 39 (28) 15
Total 1988–2018 13,467(13,326 c) 1714
b - 862 (817 c) 394 b 344 (253 c) 156 b
a The annual periods of time were from 11 September 1988 to 11 September 1991 and from 12 September 1991 to 11
September 1994, and so on. b These were different farms, not the sum of farms. c In brackets: visits for calendar
month used in the studies on occurrence.
We visited farms in 47/50 provinces. Most were meat production farms (1704 of the 1714), 4 farms
housing Rex rabbits for fur production, 3 with dwarf rabbits and 3 with New Zealand rabbits for
laboratory purposes. Most farms housed does (1677 of the 1714), mainly with weaned rabbits in the
same farm, and often in separated barns. In addition, there were 14 farms with weaned rabbits only
and 23 with males only. On all of the farms visited during the 30 years, the rabbits were kept in
conventional individual housing without elevated platforms; however, on the 200 doe farms visited
from the end of 2014 to 2018, approximately 77.5 % had installed footrests.
3.2. Visits to Farms
We made 13,467 visits to farms during the 30-year study. Our assessment of relative annual and
monthly occurrences of clinical diseases was based on one visit per farm and calendar month, at most,
as we have explained in Section 2.4 (statistical analysis); hence the figure 13,326. In total, 862 visits
were made due to myxomatosis, 817 without repeated visits in the same month (–5.2%), to 394 farms.
For RHD, 344 visits were made, 253 also without monthly repetitions (–26.5%), to 156 farms. Table 2
shows the number of visits for all the months.
Table 2. Visits per month due to myxomatosis (myxo.) and rabbit haemorrhagic disease (RHD),
and number of farms visited from September 1988 to September 2018.
Month a N Visits Total (b)
N Visits due to
myxo. (b) N Farms with myxo.
N Visits due to RHD.
(b)
N Farms with
RHD
January 1054 (1035) 89 (71) 71 20 (17) 17
February 1122 (1113) 81 (77) 76 18 (13) 13
March 1176 (1165) 80 (72) 71 31 (26) 25
April 1113 (1098) 66 (65) 63 44 (32) 30
May 1131 (1126) 56 (55) 52 26 (22) 22
June 1107 (1091) 35 (33) 32 37 (23) 20
July 1195 (1180) 50 (49) 49 54 (42) 32
August 1157 (1145) 60 (59) 57 39 (26) 23
September 1160 (1155) 104 (103) 99 12 (10) 10
October 1151 (1131) 97 (90) 83 27 (16) 16
November 1001 (995) 64 (63) 62 19 (13) 13
December 1100 (1092) 80 (80) 76 17 (13) 12
Total 13,467 (13,326 b) 862 (817 b) 394 c 344 (253 b) 156 c
a The total number of visits for all the months of January, February, and so on, during the 30-year study. b In brackets:
visits for calendar month. c These were different farms, not the sum of farms.
The number of monthly visits during the 30 years was similar; this contributed to preventing bias.
3.3. Diagnosing Myxomatosis
We based our on-farm diagnostic procedures of myxomatosis on clinical examination of live
rabbits, and sometimes with dead animals. Differential diagnosis was necessary (1) in 2-week-old
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rabbits, (2) in cases of concurrent diseases such as dermatophytosis or rhinitis, (3) in peracute forms
resulting in death, and (4) in rabbits previously vaccinated against myxomatosis. An atypical case of
myxomatosis in a female can be seen in a video on our website: https://www.cunivetservice.com/en [43].
3.4. Diagnosing Rabbit Haemorrhagic Disease
During the 344 visits and in necropsies we made due to RHD, we observed different degrees of
evolution of the disease based on the contents of the stomach (full or empty). We have related a full
stomach with an acute process; according to Cooke [44]: “(sick) rabbits . . . may even continue to eat
sporadically a few hours or sometimes minutes before death”. During the first years of the study,
we found affected adults and weaned rabbits (>35 days old), with few 23–25-day old rabbits being
affected, as observed in a previous study [20]. In January, 2011 we observed a particularly interesting
case of affected young rabbits (25-days old) due to RHDV GI.1. Months later, we started to diagnose
disease due to RHDV GI.2 infection. During the 2011–2013 GI.2 epidemics, vaccines produced with
classic GI.1 strains were not effective and the number of calls to farms increased. Unlike during
the previous GI.1 epidemics (1988–2010), during the GI.2 outbreaks we necropsied adults [45] and
young rabbits (10–35 days) or weaned rabbits. We also examined samples from on-farm suspected
but somewhat unclear cases and several specimens were sent to the laboratory, some of which were
confirmed to be bacterial septicemia, or bacterial pneumonia and RHD, simultaneously. From 2011
onwards we decided to take serosanguinous nasal discharge into consideration. Between July 2011
and September 2018 we performed 1404 necropsies on 102 farms, the apparent cause of death being
RHD caused by GI.2. We observed serosanguinous nasal discharge in 18.6 % of cases (261/1404).
3.5. Analysis of the Studied Risk Factors
Table 3 shows the results of the analysis of variance for the categorical data, corresponding to the
model explaining the occurrence of myxomatosis and RHD, showing the significance of the year and
month effect.
Table 3. The CATMOD (analysis of categorical model) of the risk factors year and month for the
occurrence of myxomatosis and rabbit haemorrhagic disease (RHD), from 1988 until 2018.
Source DF
Myxomatosis RHD
Chi-Square Pr > Chi-Sq Chi-Square Pr > Chi-Sq
Year 29 178.61 <0.0001 226.13 <0.0001
Month 11 44.87 <0.0001 36.65 <0.0001
3.6. Relative Prevalence of Myxomatosis
3.6.1. Annual Prevalence of Myxomatosis
Figure 2 shows mean and annual (relative) prevalence of myxomatosis. We have also included the
rolling average and trend. For example, there were 32 visits due to myxomatosis and 194 total (calendar
month) visits from 11 September 1988 until 31 December 1988 (16.5% annual relative prevalence).
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Figure 2. Mean annual prevalence of visited farms with clinical myxomatosis, rolling average for
three years (dotted line) and trend, based on 817 visits to 394 affected farms. A total of 13,326 visits
(calendar month) were made to 1714 farms in Spain, from 1988 to 2018.
Mean relative annual prevalence of clinical myxomatosis on the farms was 6.5% throughout the
30-year study period. There were apparently three prevalence peaks (rolling average): 1997, 2005,
and 2013; we did not analyze the causes, e.g., the climate variables. Annual prevalence decreased from
12.6% in 1989 to 5.3% in 1995 (rolling average). Our hypothesis is that vaccination schedules were
improved. Vaccines made with attenuated homologous virus strains were not used extensively until the
1990’s. Thus, on 95.5% of 200 farms housing does visited from the end of 2014 to 2018, future breeders
and adult females were vaccinated against myxomatosis; “homologous” vaccines were used on 90.6% of
them. We paid particular attention differentiating to which groups of does the booster should be applied;
for example, taking into account variables such as a) the type of farm, e.g., in selection farms, the does
were not revaccinated, (b) we asked when females were last vaccinated with “homologous” vaccine
(in general, we recommend revaccination from 6 to 8 months onwards). Furthermore, we considered
cases where the maternal or the vaccinal immunity might have waned or the immune system was
affected, due to predisposing risk factors such as gastroenteric diseases, or enabling risk factors, e.g.,
overexposure to vaccine antigens. In the case of predisposing risks, we recommended revaccination,
but in other situations (e.g., overexposure) we did not suggest revaccination.
3.6.2. Monthly Prevalence of Myxomatosis
We analyzed the seasonal effect based on results for relative monthly prevalence. For instance,
from Table 2, dividing 71 visits due to myxomatosis during January of the 30-year, by 1035 total visits
(calendar month) (Figure 3). Mean monthly relative prevalence was 6.1%. We observed the highest
peak in September (8.9%) and the lowest prevalence in June (3%).
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Figure 3. Monthly relative prevalence of clinical myxomatosis and standard error of the mean, based on
817 visits to 394 affected farms. A total of 13,326 visits (calendar month) were made to 1714 farms in
Spain, from 1988 to 2018.
In Spain, mosquitoes and flies are usually more abundant on farms from August to October,
although this varies from farm to farm; in the present study we did not find flea infestations.
3.7. Relative Incidence of Rabbit Haemorrhagic Disease
3.7.1. Annual Incidence of RHD
Figure 4 shows the evolution of the relative annual incidence of RHD. The annual mean throughout
the 30-year study period was 1.9%.
There were two serious epidemics, during 1988–1989 and 2011–2013, with different mean relative
incidences, reaching maximum levels of 5.5% in 1989 and 11.3% in 2013. The GI.1 epidemic occurred due
to lack of protection as there was no vaccine available; while the GI.2 epidemic occurred demonstrating
a lack of cross protection of the GI.1 based vaccines. With regard to vaccination against RHD, on the
200 doe farms visited from the end of 2014 to 2018, 97.5% of the does were systematically vaccinated
against RHDV GI.2 or against RHDV GI.1 as well. In June 2019, GI.1 or GI.2 based vaccines were
available. In our vaccination schedule against RHD, following the criterion of Capucci et al. [46],
we suggested vaccinating future breeders against classic RHDV (GI.1) and against new RHDV (GI.2);
boosters were only recommended against GI.2 in adults. Following the serious 2011–2013 epidemics,
the incidence of RHD remained higher than during 1990-2010. In our opinion, this was due to the
recurrent outbreaks of RHD on the same farm, mainly in non-vaccinated weaned rabbits or runts.
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farms. A total of 13,326 visits (calendar month) were made to 1714 farms in Spain.
There were no significant differences in relative monthly incidence during the first period
(1988–2018), probably due to the lower incidence of RHD.
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4. Discussion
In relation to the limitations of this retrospective study, and the characteristics of the visited farms,
although this was a convenience sample, as the first author had access to the farms; the total number
in the study, 1714, was high. Besides the described sizes of the visited farms, there were several risk
factors related with housing and management practices, not recorded for all the farms; e.g., the number
of batches per farm, the line of rabbits, the rhythm of reproduction, and so on. We did not analyze these
factors to avoid confounding or bias. In a previous study we described several of these variables in
detail [34]. Concerning myxomatosis, the all-in all-out system allowed cleaning and disinfection of the
barn after the sale of the rabbits, which had sanitary advantages, e.g., avoiding contagions (results not
presented), in agreement with Huneau-Salaün et al. [47].
The aim of diagnosing myxomatosis on farms was at herd level, not clinical-individual assessment
per se, which would be of interest in pet rabbits [48], but early detection and culling of sick rabbits,
as a key biosecurity measure. On-farm differential diagnosis was necessary, e.g., on farms housing
vaccinated rabbits; in such cases, signs and lesions could be moderate, often with a mild clinical aspect.
We also had difficulty with the clinical interpretation of some cases of unapparent carriers of MYXV
being detected after vaccination, as indicated in [49].
In relation to RHD diagnosis, we did not score the clinical events in all of the affected rabbits,
which would be more recommendable when examining smaller colonies [50]. From mid-2011 onwards
we paid special attention to serosanguinous nasal discharge, which Liu et al. [51], described as
typical of RHD caused by the classic virus (RHDV GI.1). This finding is of interest for two reasons.
Firstly, because according to our observations, serosanguinous nasal discharge is not a pathognomonic
sign of RHD caused by GI.2; we coincide with [50]. Evidently, the most serious fact is that rabbit
producers rule out the presence of RHD when serosanguinous nasal discharge is not observed.
Secondly, we observed the presence of blood on the nose in cases of myxomatosis, rhinitis and
pneumonia, acute mastitis, in rabbits affected by mucoid enteropathy (similar to epizootic rabbit
enteropathy) [52]; this could also have occurred due to the existence of Clostridium spp., which produces
hemolytic toxin [53].
This 30-year study provided epidemiological information of myxomatosis and has enabled us to
better assist the rabbit producers with their vaccination’s schedules. Also, as reported in a previous
study it has made the continuous training and motivation of farm staff possible, based on technical
evidence [34]. Vaccination is a key aspect of myxomatosis control. According to our observations, the
percentage of farms using vaccines elaborated with homologous strains of MYXV increased from 1988 to
2018; this could have a favorable effect on decreasing the prevalence of myxomatosis. During 2014–2018
producers vaccinated against myxomatosis on 95.5% of the 200 visited farms; 90% of vaccines used
were “homologous”. From 2010 till 2013 there were 274 visited rabbitries: 93.6% vaccinated, 88% with
a “homologous” one. In 1994 we visited 193 farms; producers vaccinated against myxomatosis in
81% of cases. In the same year, 59% used “homologous” vaccines either alone or after administering
a “heterologous” one [32]. We explicitly monitored and supervised the occurrence of myxomatosis, the
protection of vaccines on farms, and the diagnosis of side effects, as indicated by Knight-Jones et al. [54].
Post-vaccination side effects on visited farms could not be related to each individual, as is the case in pet
rabbit clinics [55], nor was it possible to study each side effect in detail. Possible vaccine failures due to
causes related to its origin, transport or inadequate administration, is an interesting matter (as pointed
out in [56]). Apart from errors related to biosecurity, e.g., inefficient culling of sick animals showing
mild signs, such failures could also explain the endemic persistence of myxomatosis, even though
vaccination was implemented on 95.5% of the farms we visited.
Our monthly visits from 1988 to 2018 were homogeneous; therefore, it was possible to compare
the relative monthly prevalence of clinical myxomatosis. In relation to epidemics between November
and March, when temperatures were low, Fenner and Ratcliffe [14] described the favorable effect of
cold weather, as MYXV is thermolabile; “the disease is less severe and lethal at higher temperatures”.
However, “”ambient temperature has no direct effect on the course of RHD in infected rabbits” [44].
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In winter, MYXV causing atypical myxomatosis is airborne, whether insects are present or not; however,
evidently, they contribute to the spread of the disease in summer and autumn. We advised producers
to heat their doe barns to prevent cold weather from weakening their immune system, in accordance
with Moberg [57]. Our results suggest that myxomatosis occurrence in domestic rabbits is similar to
that observed in wild rabbits by Ross et al., [58] during 1971–1978. Arthur and Louzis [59] studied
classic myxomatosis during 1953–1965, and the atypical form since 1979; in the first case, there were
more epidemics in August–October, whereas in the second, they also occurred in winter. In Spain,
according to Villafuerte et al [60] from 2003 to 2009 there was a higher occurrence of myxomatosis
in wild rabbits during summer and autumn. Some years, there were outbreaks during winter [61],
depending on the rainfall and the availability of food, the reproductive activity and the presence of
susceptible young rabbits [62].
Clinical myxomatosis was clearly endemic on several farms; we could not exclude the cases of
unapparent carriers [63], the epidemiological importance of which was difficult to determine, as in the
case of RHD, according to [64]. For this reason, and despite seasonality, we recommend keeping future
breeders and adult rabbits systematically protected by vaccination, as we have already suggested [15].
We do not recommend “heterologous” vaccines in pregnant does, in agreement with [49]. We
diagnosed fibromatosis on a number of occasions, in spontaneous cases in adults, as indicated in [65]
or compatible with vaccination in young rabbits under 25–28 days old [5]. Our interest also lies in
concurrent diseases, such as digestive and respiratory diseases, previously studied by Marlier et al. [66],
taking into account the immune suppressing effect of MYXV [67], and their interactions. With regard to
immunoprophylaxis, we wonder how so many cases of myxomatosis occur despite the high percentage
of farms applying vaccination. Greater knowledge of the protection of breeding rabbits and application
of boosters is a key challenge for the future. In addition, continuous progress must be made in
biosecurity practices.
In reference to RHD, we do not know the causes of higher incidence during April–August.
Perhaps this epidemiological result differs from the wild, due to climate and environmental variables
affecting wild rabbits more intensively [68]. Producers used the vaccines when they were available;
in the present study the ratio was 97.5%. On 274 farms visited during 2010–2013, 95% of the does
were vaccinated against GI.1; vaccine made with GI.2 virus was first used in Spain in July 2013 [32].
We observed outbreaks of RHD in different farms, and recurrently on same farms. Besides the
susceptibility of the host, this could have been due to the persistence of the virus on the farm.
Henning et al. [69] observed that the virus remained infective for up to three months under field
environment conditions. Another possibility was the presence of the viruses within the area around
the farm; e.g., due to the existence of carrier micromammals [70]. The possibility of asymptomatic
infections with carriers [71] and excreters existing for 2 months after vaccination is of great interest in
the control of RHDV GI.2 [50].
5. Conclusions
In this retrospective study we assessed the relative occurrence of myxomatosis and rabbit
haemorrhagic disease (RHD) in domestic rabbits. To do this, we used a database containing information
on 13,326 visits to 1714 farms, located in Spain. The study lasted from 1988 to 2018. Our data indicate
two RHDV epidemics: 1988–1989 due to RHDV GI.1, and 2011-2013 due to RHDV GI.2. The data
show that the GI.1 epidemics occurred during periods of lack of protection. In 1988–1989 there was no
vaccine available. While the GI.2 epidemic occurred demonstrating a lack of cross protection of the GI.1
based vaccines. Agreeing to our observations, serosanguinous nasal discharge is not linked to RHD
caused by RHDV GI.2. Analysis of annual and monthly relative prevalence of myxomatosis and mean
relative incidence of RHD according to year and month suggest that these variables affect both diseases.
Therefore, it may be inferred from our study that future breeders and adults should be systematically
protected by vaccination, particularly before the periods when occurrence is higher. Both diseases
remain prevalent; however, effective vaccination has produced a steady decline in myxomatosis and
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RHDV GI.1 and GI.2 on-farm detection. The maintenance of high hygienic standards will be required
to continue and improve this control. However, further studies must be carried out to investigate the
causes of sustained virus presence and vaccine breaks.
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